Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RTA 1701 capsules
RTA 1701 · 1 trial · 1 indication
Safety will be assessed based on the number of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Single Dose of RTA 1701 or Placebo | EXPERIMENTAL | RTA 1701 capsules or placebo taken orally in a single dose. Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo |
| Multiple Dose of RTA 1701 or Placebo | EXPERIMENTAL | RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks. Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo |
| Name | Type | Description |
|---|---|---|
| Placebo oral capsule | DRUG | Placebo capsule matched to an RTA 1701 capsule |
| RTA 1701 capsules | DRUG | Capsule containing RTA 1701, multiple dosages |
Inclusion Criteria: * Male or female and age is between 18 and 55 years, inclusive; * Female participants of childbearing potential must: * Not be pregnant, or lactating, or planning a pregnancy, and * Be willing to use contraception (hormonal contraceptives, diaphragm, or intrauterine contraceptio...
RTA 1701 is an investigational small molecule drug developed by Biogen Inc. (ticker BIIB). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
RTA 1701 is being developed by Biogen Inc., which trades on the Nasdaq under the ticker symbol BIIB. Biogen is the company responsible for the research and clinical development of RTA 1701.
RTA 1701 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
RTA 1701 has been evaluated in a single Phase 1 trial, NCT03579030, titled Safety and PK/PD of RTA 1701 in Healthy Adults. The trial enrolled 90 healthy volunteers in Australia and has been completed.
Yes, RTA 1701 capsules is another name for RTA 1701. Both refer to the same investigational small molecule developed by Biogen Inc. The capsule form is the oral dosage studied in clinical trials.